National Pharmacy Association (NPA) - News updates

Certain pages on this news feed are only available to NPA members and hence requires members to log-in accordingly


Class 2 pharmacy level medicines recall – Action within 48 hours – ranitidine products

DRUG ALERT Class 2 medicines recall – Action within 48 hours – Ranitidine products (Creo Pharma Limited (Zentiva Pharma UK Ltd) and Tillomed Laboratories Limited) Ref: EL (19)A/36 19 November 2019 Ranitidine oral solution 30mg/1ml – PL 31862/0023 (Manufactured by Creo Pharma Limited (Zentiva Pharma UK Ltd) Ranitidine tablets 150mg – PL 11311/0138 (Manufactured by Tillomed Laboratories Limited) A Class 2 medicines recall has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA) for two ranitidine products. – this is a pharmacy level recall alert which requires action within 48 hours of the alert being issued on 19 November 2019: Creo Pharma Limited (Zentiva Pharma UK Ltd) and Tillomed Laboratories Limited are recalling all unexpired stock of the above preparations from pharmacies due to potential contamination of ranitidine with N-nitrosodimethylamine (NDMA) as an impurity — this is a precautionary measure as NDMA has genotoxic and carcinogenic potential. Advice for healthcare professionals, including pharmacy teams Pharmacists and pharmacy teams are required to: Stop supplying the affected products immediately Quarantine all remaining stock and return it to the supplier using their agreed process Provide the following advice to patients making enquiries about the issue: Do not stop taking their medicines – stopping treatment can pose more of a health risk than the contaminant presents Patients do not need to see their doctor until their next routine appointment/treatment review Speak to their doctor if they have concerns Creo Pharma Limited (Zentiva Pharma UK Ltd) can be contacted as below: Stock control enquiries – contact the Customer Services team on 0844 8793 188 or GFD-CUSTOMERSERVICES@zentiva.com Medical information enquiries — contact the Medical Information team on 800 090 2408 or UKMedInfo@zentiva.com Tillomed Laboratories Limited can be contacted as below: For all enquires email qa@tillomed.co.uk Stock should be returned to following address: Mawdsley Brooks Redhouse Rockingham Way Adwick-le-Street Doncaster DN6 7FB Produced by the NPA Pharmacy Services team November 2019.…

Pharmacy bodies unite to promote community pharmacy in the 2019 General Election

Class 3 medicines recall – Action within five days: Folic acid tablets 5mg (Accord UK Ltd)

DRUG ALERT Class 3 medicines recall – Action within five days: Folic acid tablets 5mg (Accord UK Ltd) Ref: EL (19)A/35 Date: 18 November 2019 Folic acid tablets 5mg (Manufactured by Accord UK Ltd) PL 0142/5522 A Class 3 wholesaler level medicines recall has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA) for a specific batch number of Folic acid tablets 5mg manufactured by Accord UK Ltd. Further information can be found on the MHRA section on the GOV.UK website. Produced by the NPA Pharmacy Services team November 2019.  …

Electronic Prescription Service (EPS) Phase 4 — template SOP and guidance launched (England)

Phase 4 of the Electronic Prescription Service (EPS) is being rolled out nationally from Monday 18 November 2019.  What is EPS Phase 4? In the next phase of the Electronic Prescription Service (EPS), the electronic prescription, rather than the paper prescription will be the default method of prescribing, dispensing and reimbursing NHS prescriptions in England. Currently, only patients who have set up a nomination with their chosen pharmacy can use EPS; however in EPS Phase 4, prescriptions will be generated electronically even for patients who have not set a nomination. This new functionality can increase the number of electronic prescriptions processed from 70% to above 95%. Approximately 60 GP practices across England are now able to use EPS Phase 4. A staggered roll out of EPS Phase 4 across GP practices will proceed from Monday 18 November 2019 as follows: TTP SystmOne – begins on 18 November 2019 and will take place over the following months EMIS, Vision and Microtest – to be published soon on the national roll out schedule page Some GP practices will go live with EPS Phase 4 earlier than others. Where a patient receives an EPS Phase 4 token from one of these practices, they can choose to take it to any pharmacy in England.…

Diamorphine injection 5mg and 10mg (Accord-UK Ltd brand) and Uniphyllin® Continus® tablets all strengths – medicine shortages

The NPA would like to inform you of the following medicine supply issues:  Diamorphine injection 5mg and 10mg (Accord-UK Ltd brand) The Department of Health and Social Care (DHSC) has issued a medicine supply notice that Accord-UK Ltd is unable to satisfy current UK demand for diamorphine injection 5mg and 10mg due to ongoing issues at its manufacturing site. In addition, Wockhardt UK Ltd, the only other manufacturer of diamorphine injection 5mg and 10mg, is unable to support the UK market in full. The shortage is anticipated to last until March 2020. The DHSC has advised that morphine injection 10mg by Hameln Pharmaceuticals ltd is available and can support the supply issue during this interim period Uniphyllin® Continus® tablets – all strengths Napp Pharmaceuticals Limited has reported an anticipated short-term supply issue of Uniphyllin® Continus® tablets in 200mg, 300mg and 400mg. The shortage is due to a manufacturing issue and is not expected to last for longer than approximately three weeks. For further information on this or any other query, please contact the NPA Pharmacy Services team on 01727 891 800 or email pharmacyservices@npa.co.uk.  Produced by the NPA Pharmacy Services team November 2019.  …

Class 2 pharmacy level medicines recall– Action within 48 hours – Sandoz Limited Omeprazole powder for solution for infusion 40mg (EL(19)A/34)

Class 2 pharmacy level medicines recall– Action within 48 hours – Sandoz Limited Omeprazole powder for solution for infusion 40mg (EL(19)A/34) Ref: EL(19)A/34 Date: 11 November 2019 Omeprazole powder for solution for infusion 40mg (Manufactured by Sandoz Limited) PL 04416/0701 A Class 2 medicines recall has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA) for a specific batch of Omeprazole powder for solution for infusion 40mg  manufactured by Sandoz Limited. Further details and information on affected batches can be found on the MHRA section on the GOV.UK website. Produced by the NPA Pharmacy Services team November 2019.…

“More important than ever” Ask Your Pharmacist Week gets underway

The Serious Shortage Protocol (SSP) for fluoxetine capsules 40mg is being extended

The Serious Shortage Protocol (SSP) for fluoxetine capsules 40mg, which was previously due to end on 11 November 2019, is now being extended with an amended end date of 20 November 2019. The SSP for fluoxetine capsules 30mg was previously extended and is also due to end on 20 November 2019 The SSPs for fluoxetine capsules in the 30mg and 40mg strengths, introduced on 3 October 2019, allow pharmacists to switch to an alternative available formulation or strength of fluoxetine. The SSP for fluoxetine capsules 10mg was withdrawn on 25 October 2019. Further information on the SSPs for fluoxetine is available on the NHS Business Services Authority website. Produced by the NPA Pharmacy Services team November 2019.…

Labour confirms to NPA they have no plans to nationalise community pharmacies

NPA chief exec on the general election campaign trail